Treatment regimens and treatments for multiple sclerosis with ofatumumab

摘要

The present disclosure is directed to a therapeutic regimen for treating multiple sclerosis (MS). These methods use administering an anti-CD20 monoclonal antibody, ofatumumab, to the patient during loading dose and maintenance regimens.